2024-09-01 - Analysis Report
## REGN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company focused on the development and commercialization of life-transforming medicines for serious diseases.

**1. Performance Analysis:**

* **Cumulative Return:** REGN has delivered a cumulative return of 159.56%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 89.66%.
* **Relative Performance:** REGN's outperformance against the S&P 500 is evident, with a current relative performance of 69.9. This places it at the 95.82 percentile of its historical performance range, indicating strong outperformance compared to its historical volatility. 

**2. Recent Price Movement:**

* **Closing Price:** $1184.69
* **Moving Averages:**
    * 5-day: $1192.81
    * 20-day: $1158.30
    * 60-day: $1090.18

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 73.51. This indicates that the stock is currently in overbought territory, suggesting potential for a near-term correction.
* **PPO (Percentage Price Oscillator):** -0.17. A negative value suggests a bearish momentum, aligning with the overbought RSI reading.
* **Delta_Previous_Relative_Divergence:** -4.18. This negative value indicates a recent short-term downtrend in relative performance, further supporting the possibility of a correction.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55B | 
| 2024-05-02 | 6.70 | $3.15B |
| 2023-11-02 | 9.48 | $3.36B |
| 2023-08-03 | 9.05 | $3.16B |
| 2024-08-01 | 9.05 | $3.16B |

The latest earnings report for Q2 2024 shows EPS of $13.25, exceeding analysts' expectations. This strong performance suggests continued growth potential. However, it's crucial to monitor future earnings reports and potential impacts of the overbought conditions.

**5. Overall Analysis:**

REGN has demonstrated strong long-term growth, significantly outperforming the S&P 500. The current overbought conditions, indicated by RSI and PPO, suggest potential for a near-term correction.  However, the recent strong earnings performance and the historical outperformance could support continued growth in the long term.  Investors should carefully consider the technical indicators and market sentiment, along with the company's future growth prospects, when making investment decisions. 

**6. Recommendation:**

Given the current overbought conditions and the recent downtrend in relative performance, REGN might be ripe for a short-term correction. Investors may consider holding existing positions or entering with caution, waiting for potential pullbacks before entering new positions.  Long-term investors can capitalize on any correction as a potential buying opportunity given the company's strong growth potential. It is crucial to monitor market sentiment, earnings reports, and potential regulatory developments that could impact the stock's future trajectory. 
